Clinical Study
Assessment of Confirmed Clinical Hypersensitivity to Rituximab in Patients Affected with B-Cell Neoplasia
Table 2
Characteristics of the population.
| Variable | Frequency (%) |
| Age (median) | 68 years (50–81) | |
| Sex | Female | 4 (40%) | Male | 6 (60%) |
| Diagnosis | Diffuse large B-cell lymphoma | 2 (20%) | Follicular lymphoma | 3 (30%) | Waldenström’s disease | 2 (20%) | Marginal zone lymphoma | 2 (20%) | Mantle cell lymphoma | 1 (10%) |
| Line of treatment | First-line | 7 (70%) | Second-line | 3 (30%) |
| Grade of reaction | Mild | 2 (25%) | Moderate | 1 (12.5%) | Severe | 4 (50%) | Life-threatening | 1 (12.5%) |
|
|